In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival
Open Access
- 19 October 2012
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 11 (1) , 78
Abstract
Background: In multiple myeloma (MM), the immunoglobulin heavy chain VDJ gene rearrangement is a unique clonotypic signature that identifies all members of the myeloma clone independent of morphology or phenotype. Each clonotypic MM cell has only one genomic copy of the rearranged IgH VDJ. Methods: Pre-treatment bone marrow aspirates from myeloma patients at diagnosis or in relapse were evaluated for the number of clonotypic cells using real time quantitative PCR (RPCR). RPCR measured the level of clonal cells, termed VDJ%, in 139 diagnosis and relapse BM aspirates from MM patients. Results: Patients with a VDJ% below the median had a significantly longer event free survival (EFS) then those with a VDJ% higher than the median (p=0.0077, HR=0.57). Further, although the VDJ% from non-transplant patients predicted EFS (p=0.0093), VDJ% failed to predict outcome after autologous stem cell transplant (p=0.53). Conclusions: Our results suggest that for non-transplant patients, the tumor burden before treatment, perhaps reflecting cancer stem cell progeny/output, is an indirect measure that may indicate the number of MM cancer stem cells and hence event free survival.Keywords
This publication has 46 references indexed in Scilit:
- Circulating plasma cells predict the outcome of relapsed or refractory multiple myelomaLeukemia & Lymphoma, 2012
- In multiple myeloma, bone‐marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survivalAmerican Journal of Hematology, 2012
- Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneBlood, 2011
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Blood, 2011
- Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implicationsBlood, 2011
- Predictive Value of Post-Transplant Bone Marrow Plasma Cell Percent in Multiple Myeloma Patients Undergone Autologous TransplantationThe Korean Journal of Internal Medicine, 2011
- Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patientsHaematologica, 2009
- Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasoneBlood, 2009
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBlood, 2008
- Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose TherapyJournal of Clinical Oncology, 2008